explore -WSS

explore

author：explore 2025-10-02 00:39:29 - browse：2

Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million in a Series C funding round from investors including pharma company Amgen and the VC arm of AI giant NVIDIA.

Generate was founded in 2018 by venture-creation firm Flagship Pioneering to use machine learning algorithms to identify antibodies, peptides, cell therapies, and other medicines. It launched its first clinical trial in July for a Covid monoclonal antibody, and is working on starting another clinical trial for an asthma treatment.

The biotech, which is based in Somerville, Mass., has big plans for the next couple of years: It has another 15 drug candidates in the works and plans to introduce 10 more annually, CEO Mike Nally told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Some of the ways extreme heat will change life as we know it

entertainment

explore

WSS

Genentech weighs delaying cancer therapy after drug pricing law

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Large hospital system sues Multiplan for low

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Ransomware attacks on hospitals: Study outlines patient impact

Pharma budget tightening trickles down to Doximity

explore

explore

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

Peter Hotez and the public health issue of online harassment

The history of OxyContin, told through Purdue Pharma documents

Bright Health sells Medicare Advantage business to Molina

Maui funeral service workers on devastation of fires: 'I'm in shock'

Peter Hotez and the public health issue of online harassment

Ransomware attacks on hospitals: Study outlines patient impact

Alkermes shareholders re

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

explore

World's first CRISPR

Covid's long

Novo acquires Inversago for up to $1 billion

After John Oliver segment, STAT readers share their opioid

Surge of respiratory disease in China has likely explanation

Large hospital system sues Multiplan for low

hotspot

entertainment

explore

focus